Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
So low cost! It's worth geting penis vibrator in our Sex Toys Store.
Popular Articles

Fallopian Tubes Offer New Stem Cell
Human tissues normally discarded after surgical procedures could be a rich additional of stem cells for regenerative medicine. New research from BioMed Central"s open access Journal of Translational Medicine shows for the first time that human fallopian tubes are abundant in mesenchymal stem cells which have the potential of becoming a variety of cell types.
pharmacy online Dentisti fiume
Lowell Elementary Closes Due To High Rate Of Influenza Like Illness
Today, the Maricopa County Department of Public Health in cooperation with Phoenix Elementary School District has closed Lowell Elementary School until May 26, 2009 due to a high rate of influenza like illness.
News of the day
New Jersey Senator Proposes Plan To Avert HIV/AIDS Drug Copayments
New Jersey state Sen. Joseph Vitale (D) -- chair of the Senate Health, Human Services and Senior Citizens Committee -- earlier this week proposed a plan to temporarily reduce rebate checks to senior citizens earning $100,000 to $150,000 in an effort to alleviate the effects of possible budget cuts on certain populations, the Newark Star-Ledger reports. Vitale"s proposal also would avert planned $6 to $15 prescription drug copayments for people living with HIV/AIDS in the state (Livio, Newark Star-Ledger, 5/12). The copayments are part of Gov. Jon Corzine"s (D) $29.8 billion spending proposal for the state"s new fiscal year and would collect $1.36 million by creating copayments for HIV/AIDS drugs based on a sliding scale determined by income. The copayments would affect 9,000 people living with HIV/AIDS who have obtained no-cost medicine from the state because they do not qualify for other assistance programs. Advocates said that the copayments will hurt patients who are already struggling because of the poor economy (Kaiser Daily HIV/AIDS Report, 4/23). According to the Star-Ledger, Vitale"s proposal would save the state $15.7 million, including $9.7 million needed to allow 17,000 low-income families to enroll in the state"s health insurance program, FamilyCare. Senate Budget Committee Chair Barbara Buono (D) said that she does not believe it is possible to restore program cuts "given the collapse of revenues." According to the Office of Legislative Services, the current deficit for this year"s budget, which ends June 30, is at least $1.2 billon. Vitale said, "Our convictions are going to be tested as we come to terms with the fact that we simply don"t have enough money to fund all of the state"s priorities." He added, "But unless funding is restored for programs like NJ FamilyCare, Medicaid drug benefits and the AIDS Drug Distribution Program, I will be voting against the" fiscal year 2010 budget (Newark Star-Ledger, 5/12).
Nutrition

Genetic Immunity, InPlay Completes Patient Enrollment In Phase II Trial Of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate

Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary"s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis. Genetic Immunity is pleased to announce completion of patient enrollment in the Company"s Phase II randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, immunogenicity, and antiretroviral activity of DermaVir Patch in treatment-naç¯ve HIV-1-infected patients. The study is conducted in Hamburg, Germany with a total of thirty-six patients. "We are very happy with completion of patient enrollment in this seminal trial because it allows us to conclude the immunization schedule in this year. This trial has a unique design to investigate DermaVir Patch as mono-immunotherapy in HIV-infected individuals who are not treated with antiretroviral drugs. We are very excited to learn how our immune therapeutic nanomedicine affects the immune system and disease of this patient population. With this trial we plan to demonstrate the safety and efficacy of DermaVir Patch as monotherapy administered every 6 weeks for the treatment of HIV," commented Julianna Lisziewicz, CEO of Genetic Immunity. This novel plasmid DNA-based nanomedicine vaccine candidate, DermaVir Patch, has been under development in the last ten years. Phase I trial showed preliminary safety and tolerability and induction of memory T-cell immunity in all HIV-1-infected individuals. DermaVir is based on a single plasmid DNA capable to express most HIV antigens and to form a virus-like particle (VLP+). Plasmid DNA is formulated with a polymer to mimic a pathogen. DermaVir enters into the body via the Langerhans cells of the skin and induces memory immune responses in the lymph nodes. The primary outcome of this phase II study measures safety and tolerability of DermaVir Patch, while secondary outcome includes HIV-1 RNA measurements to assess the antiretroviral activity of the DermaVir Patch, changes in CD4+, CD8+ T-cell counts and HIV-specific immunogenicity during DermaVir Patch treatment. The study randomized patients into one of 6 arms: Arm 1 patients will receive low dose DermaVir patch (0.2 mg DNA, n=9); Arm 2 patients will receive low dose placebo patch (n=3); Arm 3 patients will receive medium dose DermaVir patch (0.4 mg DNA, n=9); Arm 4 patients will receive medium dose placebo patch (n=3); Arm 5 patients will receive high dose DermaVir patch (0.8 mg DNA, n=9); Arm 6 patients will receive high dose placebo patch (n=3). Immunization will be done on days 0, 42, 84, and 126. The total number of patches that a patient will receive throughout the study will be 8, 16, or 32 in the low, medium, and high dose arms, respectively. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thighs. The same skin sites might be used for all patch immunizations that last for 3 hours. Patients will be on-study for 282 weeks. The immunizations will be administered over an 18-week period with an identical follow up schedule continuing until week 24; patients will be followed for an additional 24 weeks for additional safety and immunogenicity evaluations. An additional 234 weeks safety follow-up will be performed including chemistry and hematology assessments and physical examinations. For more information please visit the Company"s official website at http://www.geneticimmunity.com About Genetic Immunity Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. Power of the Dream Ventures


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009